Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03564444 · ClinicalTrials.gov registry record · Phase 4

D2560C00015 FluMist Annual Safety Study 2018

A Phase 4 study, sponsored by MedImmune.

Completed
Registry status
Phase 4
Development phase
300
Enrollment target

NCT03564444 is a Phase 4 study that has completed, run by MedImmune. The registered enrollment target is 300 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03564444, a Phase 4 study, has completed, sponsored by MedImmune.

COMPLETED
Registry status
Phase 4
Development phase
300 participants
Enrollment target

Study Summary

This prospective annual release study is designed to evaluate the safety of 2 new influenza virus vaccine strains to be included in FluMist Quadrivalent for the 2018-2019 influenza season.

Interventions

  • OTHER Placebo
  • BIOLOGICAL Bivalent influenza vaccine

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2018-06-06
Est. Completion 2018-12-27
Phase Phase 4

Sponsor

MedImmune

210 total trials

What the Registry Record Tells You About NCT03564444

The ClinicalTrials.gov registry entry for NCT03564444 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT03564444 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03564444 about?

NCT03564444 is a clinical study titled "D2560C00015 FluMist Annual Safety Study 2018". This prospective annual release study is designed to evaluate the safety of 2 new influenza virus vaccine strains to be included in FluMist Quadrivalent for the 2018-2019 influenza season.

What is the current status of trial NCT03564444?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 300 participants. The study started on 2018-06-06. Estimated completion is 2018-12-27.

What interventions are being tested in trial NCT03564444?

The interventions under investigation include: Placebo (OTHER), Bivalent influenza vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT03564444?

This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.